JYNT · JOINT Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA from consolidated operations non-GAAP | $3.6M | Q4 2025 | — |
| Adjusted EBITDA from continuing operations non-GAAP | $1.6M | Q4 2025 | — |
| Clinics closed | 36 | Full year 2025 | — |
| Clinics opened | 29 | Full year 2025 | — |
| Clinics refranchised | 41 | Full year 2025 | — |
| Comp sales | -0.4% | Full year 2025 | — |
| Company-owned or managed clinics | 75 | December 31, 2025 | — |
| Franchise licenses sold | 31 | Full year 2025 | — |
| Franchised clinics | 885 | December 31, 2025 | — |
| Patient visits | 14.4M | Full year 2025 | — |
| System-wide sales | $532.4M | Full year 2025 | — |
| Total clinic count | 960 | December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JYNT
this stock
JOINT Corp
|
$123.02M | -1.0% | +16.2% | 37.5 | 3.3% |
|
HCA
HCA Healthcare, Inc.
|
$92.77B | -10.3% | +7.1% | 14.4 | 2.6% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.63B | -11.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.19B | +32.2% | -2.3% | 13.4 | 3.5% |
|
DVA
Davita Inc.
|
$15.37B | +110.8% | +6.5% | 22.4 | 7.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JYNT | -0.9% | +1.3% | -14.6% | -1.7% | -1.0% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +0.1% | +1.3% | -22.1% | -0.9% | -9.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.